Medicenna Therapeutics (TSE:MDNA) has released an update.
Mayfair Gold Corp. has issued a rebuttal to Muddy Waters Capital’s call for a shareholder meeting to overhaul its board, emphasizing its commitment to proper governance and value creation. The company refutes Muddy Waters’ accusations of poor management practices, clarifies the state of its option pool, and stands by its compensation standards as validated by external consultants. Amidst the dispute, Mayfair remains focused on its flagship Fenn-Gib gold project in Northern Ontario.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.
